HAC (Russian)
RSCI (Russian)
Ulrichsweb (Ulrich’s Periodicals Directory)
Scientific Indexing Services

Modern solution to the problems of hair growth and loss

DOI: https://doi.org/10.29296/25877305-2022-07-15
Download full text PDF

S. Ledentsova
Consultative and diagnostic center of Saint Petersburg State Pediatric Medical University, Ministry of Health of Russia
OOO “SOGAZ” International Medical Center, Saint Petersburg

Objective. To evaluate the therapeutic efficacy of Floema® Complex in correcting androgenetic alopecia in women Subject and methods. The investigation involved 30 female patients diagnosed with androgenetic alopecia, who were divided into 2 groups according to therapy: 1) a control group of 15 patients who received mesoscooter therapy; 2) a study group of 15 patients who had topical treatment with Floema® Complex-based lotion applied to the scalp with one 1-ml pipette per night, as well as mesoscooter therapy. Therapy in both groups was performed for 3 months. Before and after treatment, all the patients underwent trichoscopy and phototrichogram using a special software and hardware FotoFinder system. To assess clinical presentations over time, survey scalp photography was done before and 3 months after therapy. Results. The study group patients were observed to have a more pronounced effect of treatment according to the following indicators: an increase in hair density in the parietal region from 191.0 (181.0–201.0) to 221.0 (207.0–228.0) (p=0.009), a decrease in the percent of telogen hair from 22.0 (16.0–33.0) to 14.0 (9.0–19.0) (p=0.116), and that in the percent of vellus hair from 23.0 (16.0-28.0) to 13.0 (11.0–16.0) (p=0.081); the control group had no significant positive changes in the condition of hair, as shown by the results of phototrichograms. Conclusion. A clinical study showed that Floema® Complex was highly effective in treating androgenetic alopecia in women.

androgenetic alopecia
Floema® Complex

It appears your Web browser is not configured to display PDF files. Download adobe Acrobat или click here to download the PDF file.

  1. Samtsov A.V., Bozhchenko A.A. Androgeneticheskaya alopetsiya: nekotorye aspekty narushenii tkanevogo metabolizma sal’no-volosyanogo apparata i sovremennye podkhody k ikh korrektsii. Klinicheskaya dermatologiya i venerologiya. 2007; 4: 4–8 (in Russ.).
  2. Weitz R. Rapunzel’s Daughters: What Women’s Hair Tells Us About Women’s Lives. New York: Farrar, Straus and Giroux, 2004.
  3. Hunt N., McHale S. The psychological impact of alopecia. BMJ. 2005; 331 (7522): 951–3. DOI: 10.1136/bmj.331.7522.951
  4. Hunt N., McHale S. Reported experiences of persons with alopecia areata. J Loss Trauma. 2005; 10: 33–50. DOI: 10.1080/153250200490890633
  5. Hunt N., McHale S. Understanding alopecia. London: Sheldon, 2004.
  6. Gan D.C., Sinclair R.D. Prevalence of male and female pattern hair loss in Maryborough. J Investig Dermatol Symp Proc. 2005; 10 (3): 184–9. DOI: 10.1111/j.1087-0024.2005.10102.x
  7. Harrison S., Bergfeld W. Diffuse hair loss: its triggers and management. Cleve Clin J Med. 2009; 76 (6): 361–7. DOI: 10.3949/ccjm.76a.08080
  8. Werner B., Mulinari-Brenner F. Clinical and histological challenge in the differential diagnosis of diffuse alopecia: female androgenetic alopecia, telogen effluvium and alopecia areata – part II. An Bras Dermatol. 2012; 87 (6): 884–90. DOI: 10.1590/s0365-05962012000600010
  9. Price V.H. Treatment of hair loss. N Engl J Med. 1999; 341 (13): 964–73. DOI: 10.1056/NEJM199909233411307
  10. Dinh Q.Q., Sinclair R. Female pattern hair loss: current treatment concepts. Clin Interv Aging. 2007; 2 (2): 189–99.
  11. Heilmann S., Kiefer A.K., Fricker N. et al. Androgenetic alopecia: identification of four genetic risk loci and evidence for the contribution of WNT signaling to its etiology. J Invest Dermatol. 2013; 133 (6): 1489–96. DOI: 10.1038/jid.2013.43
  12. Araviiskaya E. R., Mikheev G. N., Moshkalova I. A. i dr. Oblysenie. Differentsial’nyi diagnoz. Metody terapii. Pod red. E.V. Sokolovskogo. SPb: SOTIS, 2003; 176 р. (in Russ.).
  13. Headington J.T. Telogen effluvium. New concepts and review. Arch Dermatol. 1993; 129 (3): 356–63. DOI: 10.1001/archderm.129.3.356
  14. Randall V.A. Hormonal regulation of hair follicles exhibits a biological paradox. Semin Cell Dev Biol. 2007; 18 (2): 274–85. DOI: 10.1016/j.semcdb.2007.02.004
  15. Kaufman K.D. Androgens and alopecia. Mol Cell Endocrinol. 2002; 198 (1-2): 89–95. DOI: 10.1016/s0303-7207(02)00372-6
  16. Messenger A.G., de Berker D.A.R., Sinclair R.D. Chapter 66. Disorders of Hair. In: Rook’s Textbook of Dermatology. 8th ed. Oxford, UK: Blackwell Science Publications, 2010; 66.1–66.16.
  17. Hébert J.M., Rosenquist T., Götz J. et al. FGF5 as a regulator of the hair growth cycle: evidence from targeted and spontaneous mutations. Cell. 1994; 78 (6): 1017–25. DOI: 10.1016/0092-8674(94)90276-3
  18. Botchkarev V.A., Kishimoto J. Molecular control of epithelial-mesenchymal interactions during hair follicle cycling. J Investig Dermatol Symp Proc. 2003; 8 (1): 46–55. DOI: 10.1046/j.1523-1747.2003.12171.x
  19. Chen C.C., Chuong C.M. Multi-layered environmental regulation on the homeostasis of stem cells: the saga of hair growth and alopecia. J Dermatol Sci. 2012; 66 (1): 3–11. DOI: 10.1016/j.jdermsci.2012.02.007
  20. Takakura N., Yoshida H., Kunisada T. et al. Involvement of platelet-derived growth factor receptor-alpha in hair canal formation. J Invest Dermatol. 1996; 107 (5): 770–7. DOI: 10.1111/1523-1747.ep12371802
  21. Yano K., Oura H. Angiogenesis byVEGF controls hair growth and follicle size. Cell Technol. 2001; 20: 852–3.
  22. Kanti V., Messenger A., Dobos G. et al. Evidence-based (S3) guideline for the treatment of androgenetic alopecia in women and in men – short version. J Eur Acad Dermatol Venereol. 2018; 32 (1): 11–22. DOI: 10.1111/jdv.14624
  23. Paus R., Olsen E.A., Messenger A.G. Hair growth disorders. In: Wolff K.,
  24. Goldsmith L.A., Katz S.I., Gilchrest B.A., Paller As, Leffell D.J., eds. Fitzpatrick’s Dermatology in General Medicine. 7th ed. USA: The McGraw-Hill Companies Inc, 2008; 753–77.
  25. Jain R., De-Eknamkul W. Potential targets in the discovery of new hair growth promoters for androgenic alopecia. Expert Opin Ther Targets. 2014; 18 (7): 787–806. DOI: 10.1517/14728222.2014.922956
  26. Böhlen P., Esch F., Baird A. et al. Acidic fibroblast growth factor (FGF) from bovine brain: amino-terminal sequence and comparison with basic FGF. EMBO J. 1985; 4 (8): 1951–6. DOI: 10.1002/j.1460-2075.1985.tb03876.x
  27. Kawano M., Komi-Kuramochi A., Asada M. et al. Comprehensive analysis of FGF and FGFR expression in skin: FGF18 is highly expressed in hair follicles and capable of inducing anagen from telogen stage hair follicles. J Invest Dermatol. 2005; 124 (5): 877–85. DOI: 10.1111/j.0022-202X.2005.23693.x
  28. Kimura-Ueki M., Oda Y., Oki J. et al. Hair cycle resting phase is regulated by cyclic epithelial FGF18 signaling. J Invest Dermatol. 2012; 132 (5): 1338–45. DOI: 10.1038/jid.2011.490
  29. Lupo M.P., Cole A.L. Cosmeceutical peptides. Dermatol Ther. 2007; 20 (5): 343–9. DOI: 10.1111/j.1529-8019.2007.00148.x
  30. Khavinson V.Kh., Kvetnaya T.V. Regulyatornye peptidy i gomeostaz. Ross khim zhurn. 2005; XLIX (1): 112–7 (in Russ.).
  31. Kang Y.A., Na J.I., Choi H.R. et al. Novel anti-inflammatory peptides as cosmeceutical peptides. Peptides. 2011; 32 (10): 2134–6. DOI: 10.1016/j.peptides.2011.08.017